Erasca and Bristol Myers Squibb launch Phase 1/2 trial of ERAS-0015 with navlimetostat in MTAP‑deleted pancreatic cancer

Erasca (ERAS) and Bristol Myers Squibb (BMY) have entered a non‑exclusive collaboration to study a combination of Erasca’s pan‑RAS molecular glue ERAS‑0015 and BMY’s PRMT5 inhibitor navlimetostat in patients with MTAP‑deleted pancreatic ductal adenocarcinoma. Bristol Myers Squibb will sponsor the Phase 1/2 trial while Erasca will supply ERAS‑0015. Both companies retain development and commercialization rights to their respective compounds.

The partnership gives Erasca access to a major pharma sponsor and may accelerate clinical data generation for ERAS‑0015, potentially enhancing the company’s valuation. Investors should watch trial enrollment and results, which could affect ERAS share price.

  • 1Erasca and Bristol Myers Squibb announced a collaboration to evaluate ERAS‑0015 with navlimetostat in a Phase 1/2 trial for MTAP‑deleted pancreatic ductal adenocarcinoma.
  • 2Bristol Myers Squibb will sponsor the study; Erasca will supply ERAS‑0015.
  • 3The agreement is non‑exclusive and each company retains development and commercialization rights to its drug.
  • 4ERAS stock closed at $13.89, down 8.07% on the day of the announcement.
  • 5During after‑hours trading the stock was at $14.31, up 3.05%.

Sources